Location History:
- Zionsville, IN (US) (1995 - 2003)
- San Diego, CA (US) (2016)
Company Filing History:
Years Active: 1995-2016
Title: The Innovations of Andrew L. Glasebrook
Introduction
Andrew L. Glasebrook is a notable inventor based in Zionsville, Indiana. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of nine patents to his name, Glasebrook's work has had a profound impact on the treatment of autoimmune diseases.
Latest Patents
Among his latest patents, Glasebrook has developed bispecific antibodies that specifically bind both Tumor Necrosis Factor alpha (TNFα) and Interleukin-17 (IL-17). These bispecific antibodies are particularly useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS). Additionally, he has worked on 1-(4-(Substituted alkoxy)benzyl)naphthalene compounds that exhibit estrogen inhibitory activity.
Career Highlights
Glasebrook is currently employed at Eli Lilly and Company, where he continues to innovate in the field of pharmaceuticals. His work has been instrumental in advancing treatments that improve the quality of life for patients suffering from chronic conditions.
Collaborations
Throughout his career, Glasebrook has collaborated with esteemed colleagues, including David L. Phillips and Henry U. Bryant. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic solutions.
Conclusion
Andrew L. Glasebrook's contributions to biotechnology and his innovative patents reflect his dedication to improving healthcare. His work continues to pave the way for advancements in the treatment of autoimmune diseases.